Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK, Spero Therapeutics' Utebzi (tebipenem pivoxil) wins FDA approval for complicated urinary tract infections following Ph3 success
Small molecule, infectious disease, antibiotic, urinary tract infection, carbapenem, antimicrobial resistance - Read more

LabGenius Therapeutics, LG Chem collaborate on AI/ML-designed tumour-targeting multispecific antibodies, triple-digit million milestones potential
Research collaboration, oncology, AI/ML, antibody, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

F2G, Shionogi's (olorofim) matches AmBisome in Ph3 for invasive aspergillosis, enabling fresh FDA bid
Small molecule, infectious disease, antifungal, invasive aspergillosis, orotomide - Read more

D&D Pharmatech's zabopegdutide (DD01) shows 81.8% fibrosis improvement rate in Ph2 metabolic dysfunction-associated steatohepatitis trial
Protein therapy, metabolic, GLP-1/glucagon receptor agonist, MASH, liver fibrosis, AI digital pathology - Read more

Innoviva launches Nortiva Bio to develop long-acting oral medicines using Lynx platform acquired from collapsed Lyndra Therapeutics
Long-acting oral delivery, women's health, small molecule, strategic, investment - Read more

cAMPfield Therapeutics launches with $180M Series A to advance in-licensed IBD candidate prifemilast into mid-stage trials
Inflammatory bowel disease, small molecule, autoimmune, clinical-stage - Read more

Spot Biosystems launches with $40M venture financing, advancing non-viral EV gene therapy for DMD
Gene therapy, rare disease, extracellular vesicle, neuromuscular, non-viral delivery, clinical-stage - Read more

Kardigan raises $400M IPO, advancing cardiovascular drug trio including dilated cardiomyopathy treatment
Cardiovascular, small molecule, clinical-stage, rare disease - Read more

Triveni Bio raises $65M Series C to advance atopic dermatitis bispecific antibody pipeline
Autoimmune, antibody, atopic dermatitis, bispecific antibody, clinical-stage - Read more

ZYUS Life Sciences Corporation closes CAD$200K ($143K) third tranche secured loan for working capital
Clinical-stage, pain management, non-opioid, small molecule - Read more

Alvotech raises $165M public offering and private placement, advancing biosimilar medicines development
Biosimilars, biologic manufacturing, clinical-stage - Read more

Portal Biotechnologies raises $9M, advancing cell engineering platform for pharma and biotech partners
Cell engineering, platform technology, AI/ML platform, cell therapy, mechanoporation - Read more

Aplagon raises €4.8M ($5.6M) in funding to advance Phase 2 AVF maturation failure program
Clinical-stage, cardiovascular, small molecule, anticoagulant, rare disease - Read more

Legend Biotech prices $226M public offering, global cell therapy company
Cell therapy, oncology, clinical-stage - Read more

Moderna mulls acquisition of BioNTech's closing German manufacturing plants, contingent on government partnership
Manufacturing agreement, mRNA, vaccine, government partnership, acquisition - Read more

Novo Nordisk's oral Wegovy outpaces Eli Lilly's Foundayo driven by semaglutide brand familiarity, per Spherix analysis
Small molecule, obesity, competitive, market analysis - Read more

Cellares, Ori Biotech dominate cell therapy automation, holding 81% of $1.1B raised industry-wide
Cell therapy, manufacturing, operational, investment - Read more

Biogen acquires RayThera for $1B, adding preclinical anti-inflammatory small molecule pipeline candidates
Small molecule, autoimmune, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novocure's Optune Gio Ph3 trial fails to improve overall survival in newly diagnosed glioblastoma
Medical device, cancer, tumor treating fields, glioblastoma, chemoradiation, phase 3 trial - Read more

Verastem Oncology deprioritizes Avmapki/Fakzynja (avutometinib/defactinib) combo in metastatic pancreatic cancer after Ph1b/2a results
Small molecule, cancer, MEK inhibitor, pancreatic cancer, KRAS mutation, combination therapy - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here